Cargando…
Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument,...
Autores principales: | Kajani, Surina, Kajani, Raheem, Huang, Chin-Wei, Tran, Tu, Liu, Antonio K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779142/ https://www.ncbi.nlm.nih.gov/pubmed/33409112 http://dx.doi.org/10.7759/cureus.12424 |
Ejemplares similares
-
Miller Fisher syndrome: an updated narrative review
por: Noioso, Ciro Maria, et al.
Publicado: (2023) -
Miller-Fisher Syndrome in the Setting of Influenza A Infection
por: Afflu, Sharon, et al.
Publicado: (2023) -
Ophthalmoplegia Due to Miller Fisher Syndrome in a Patient With Myasthenia Gravis
por: Brusa, Roberta, et al.
Publicado: (2019) -
A Pilot Study on Serial Nerve Ultrasound in Miller Fisher Syndrome
por: Hsueh, Hsueh-Wen, et al.
Publicado: (2020) -
Non-reactive pupils as early sign of Miller Fisher syndrome
Publicado: (2020)